Skystar Bio-Pharmaceutical Reports 33% Growth in Revenue From Continuing Operations in Second Quarter Fiscal Year 2010

Gross Margin Remains at 53%; $0.33 Diluted Earnings per Share; Company Reiterates Fiscal 2010 Guidance of $45.5 Million to $47.5 Million